Avalere Commentary on HIV Prevention Policy Featured in Health Affairs Blog

  • This page as PDF


On April 9, Avalere policy experts published a piece in the Health Affairs blog about the administration’s recently launched “Ending the HIV Epidemic: A Plan for America” initiative.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

The goal of this plan is to eliminate new HIV transmissions by 2030. Approximately $291 million in federal funding has been allocated for the program in the next year and will focus on the following areas: increasing investments in geographic hotspots, collecting data to identify HIV transmissions, and creating a local HIV “HealthForce” in the targeted areas. Despite heightened awareness, access and coverage requirements for pre-exposure prophlaxis (PrEP) therapies are unclear across commercial, Medicare, Medicaid, and AIDS Drug Assistance Program markets.

In “Coverage of Federally Recommended Preventive Services: Considerations for Eliminating HIV Transmission by 2030,” Avalere experts weigh in on the challenges and opportunities associated in the PrEP market, focusing on how the administration can leverage existing authority to improve coverage and access to PrEP in public programs and the commercial market.

Read the full piece on the Health Affairs blog.

To learn more about our policy analysis capabilities, connect with us.

Webinar: Decoding the CY 2025 Advance Notice Join Avalere’s healthcare policy experts as they dissect the CY 2025 Medicare Advantage Advance Notice and discuss the future trajectory of MA in Part D and potential outcomes, headwinds, and tailwinds for health plans. Learn More
Watch the Recording
From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Vaccines and Public Health
Please enter your email address to be notified when new Vaccines and Public Health insights are published.

Back To Top